 ROCKVILLE, Md., August 3, 2021 PRNewswire -- Synthetic Biologics, Inc. NYSE American: SYN, a diversified clinical-stage company leveraging the microbiome to develop therapeutics designed to prevent and treat gastrointestinal GI diseases in areas of high unmet need, today announced an amendment to the Companys option for an exclusive license with Massachusetts General Hospital MGH to include intellectual property IP and technology related to the use of SYN-020 intestinal alkaline phosphatase IAP, the Companys proprietary recombinant version of bovine IAP, to inhibit liver fibrosis in select diseases, including nonalcoholic fatty liver disease NAFLD. 